Clinicians from the University of Utah report the death of a patient who received a mild brain injury from a ground-level fall while taking the new anticoagulant dabigatran etexilate for non–valve related atrial fibrillation. The authors describe the events that led from a mild traumatic brain injury to the man’s death, the largely irreversible dangers of massive hemorrhage from direct thrombin inhibitors such as dabigatran, and the few management options that can be used to counteract this “uncontrollable” bleeding.